Jason Lettmann, ALX Oncology CEO
July 31, 2024 04:01 PM EDT
R&D

ALX On­col­o­gy con­tin­ues its CD47 quest, re­veal­ing Phase 2 gas­tric can­cer da­ta

Max Gelman

Senior Editor

ALX On­col­o­gy re­leased topline re­sults from a Phase 2 gas­tric can­cer tri­al, build­ing on an in­ter­im read­out from late last year that left a glim­mer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump an­nounces picks for FDA, CDC; No­var­tis seeks bolt-on deals, rais­es guid­ance; RFK Jr., Elon Musk may find ...

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times